文章：

基于治疗前PSMA PET的局部高危前列腺癌患者管理 第二部分：复发预测——系统综述与荟萃分析

Management Based on Pretreatment PSMA PET of Patients with Localized High-Risk Prostate Cancer Part 2: Prediction of Recurrence—A Systematic Review and Meta-Analysis

原文发布日期：28 February 2025

DOI: 10.3390/cancers17050841

类型: Article

开放获取: 是

英文摘要：

Background and objectives: For patients with prostate cancer (PCa), PSMA PET better diagnose metastases than conventional imaging. In a systematic review and meta-analysis (INPLASY register, 2024311004), we aimed to summarize findings with pretreatment PSMA PET in patients with PCa that was localized according to conventional imaging and summarize how pretreatment PSMA PET had influence on biochemical recurrence (BCR)-free survival and overall survival (OS). Methods: We searched for publications in Pubmed, Google Scholar, ClinicalTrials.gov, and reference lists between 2016 and February 2025. We summarized biochemical recurrence-free survival in Forest plots. Results: Nine publications reported 1908 patients and showed that pretreatment PSMA PET was associated with survival. Three publications reported that pretreatment PSMA PET gave better 3–5-year BCR-free survival than conventional imaging (74% versus 57%). Two publications reported PSMA PET-risk for 389 patients. Those with PSMA PET-low-risk lived 5 years longer often than those with PSMA PET high-risk (84% versus 20%). Conclusions: Pretreatment PSMA PET is widely used in the real world. Pretreatment PSMA PET supports personalized treatment and may explain why pretreatment PSMA PET improved BCR-free survival and OS. It is believed that pretreatment PSMA PET may facilitate future progress in care of patients with high-risk PCa.

摘要翻译： 

背景与目的：对于前列腺癌（PCa）患者，PSMA PET在诊断转移灶方面优于传统影像学检查。在一项系统综述与荟萃分析（INPLASY注册号：2024311004）中，我们旨在总结传统影像学诊断为局限性前列腺癌患者接受治疗前PSMA PET检查的结果，并分析治疗前PSMA PET对无生化复发生存期（BCR）和总生存期（OS）的影响。方法：我们检索了2016年至2025年2月期间PubMed、Google Scholar、ClinicalTrials.gov及参考文献列表中的相关文献，并通过森林图汇总了无生化复发生存期数据。结果：九篇文献共报告1908例患者，显示治疗前PSMA PET与生存期相关。其中三篇文献报道，与传统影像学相比，治疗前PSMA PET可使3-5年无生化复发生存率显著提高（74%对57%）。两篇文献报告了389例患者的PSMA PET风险分层：PSMA PET低风险患者较高风险患者常获得更长的5年生存期（84%对20%）。结论：治疗前PSMA PET已在临床实践中广泛应用。该检查有助于实现个体化治疗，并可解释其提升无生化复发生存期和总生存期的机制。我们认为，治疗前PSMA PET可能推动高危前列腺癌患者诊疗的未来进展。

原文链接：

Management Based on Pretreatment PSMA PET of Patients with Localized High-Risk Prostate Cancer Part 2: Prediction of Recurrence—A Systematic Review and Meta-Analysis